Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, discusses treatment options for transplant-ineligible Hodgkin lymphoma (HL) patients, highlighting the promise of targeted agents such as brentuximab vedotin, nivolumab and pembrolizumab, and the long-term benefits of these agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.